Bioma achieves this by delivering good bacteria to the gut, hence balancing the microbiome. Nourishing prebiotics to ...

Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika’s website, www.anika.com. An archive of the presentation will also be available on the website.

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the ...

Pipeline programs: Design continues to progress preclinical activities for its myotonic dystrophy type-1 (DM1) program toward the selection of a development candidate later in 2025. In Huntington’s ...

In this single-arm trial, the median overall survival (OS) observed was 4.0 months (95% CI: 2.5-7.2) among all 64 adults in the primary efficacy analysis based on the Kaplan-Meier estimate. The median ...

While analyzing the customer reviews of PrimeBiome, we primarily focused on whether customers have any major complaints ...

Randomised trial, 20-week treatment protocol plus 6-month follow up ...

In light of the preliminary Q1 results and the integration of the Danish-based freight forwarder DTK, we are updating our full-year outlook for 2025 as follows: Adj. EBIT of DKK 560 - 630 million ...

In collaboration with a Stanford University research team, Scenic Biotech identified and characterized PLA2G15 as a novel target in lysosomal storage diseases ...

Note: alfa pump® and DSR® are registered trademarks.

With this appointment, Pramana further strengthens its world-class scientific team spanning metabolic disease, cardiovascular biology, and neurology. Together, this group is advancing a bold vision: ...